Navigation Links
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Date:9/21/2007

ultiforme, pruritus.

Cardiovascular and cerebrovascular: Uncommon: Myocardial infarction, angina pectoris, cerebrovascular accident, arrhythmias, transient ischaemic attack. (Usually when given in combination with other cytotoxic agents and with pre-existing cardiovascular risk.) Common: Chest pain.

For full details of these and other side-effects, please see the Summary of Product Characteristics, which is available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/alimta/H-564-PI-en.pdf

GEMZAR ABBREVIATED PRESCRIBING INFORMATION

Uses

GEMZAR is indicated for the treatment of adults with:

Non-Small Cell Lung Cancer (NSCLC)

Combination use: In combination with cisplatin as a first-line treatment of patients with locally advanced (inoperable Stage IIIA or IIIB) or metastatic (Stage IV) NSCLC.

Single-agent use: The palliative treatment of patients with locally advanced or metastatic NSCLC.

Pancreatic Cancer

The treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas, including those with 5-FU refractory pancreatic cancer.

Bladder Cancer

The treatment of advanced bladder cancer (muscle invasive Stage IV tumours with or without metastases) in combination with cisplatin therapy.

Breast Cancer

In combination with paclitaxel for patients with metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline, unless clinically contra- indicated.

Dosage and Administration

The drug is only administered intravenously and not more than once per week.

Non-Small Cell Lung Cancer - Combination Use

Gemcitabine in combination with cisplatin has been investigated using two dosing regimens (three week schedule or four week schedule).

The three week schedule used gemcit
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment
2. Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Malvern initiates European user group meetings for chemical imaging
9. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
10. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
11. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Unchained Labs, a refreshingly new biologic tools ... conference and launches the UNit — the first and ... Essential Protein Engineering Summit takes place in ... UNit lets drug discovery researchers look at more protein ... 7 applications, 144 sample a day throughput and 9 microliter sample ...
(Date:5/4/2015)... May 4, 2015 Intarcia Therapeutics, ... Michael Williams into the newly created role ... a senior pharmaceutical executive with world-class experience – ... and distinguished service at industry leaders such as ... a broad range of therapeutic areas, including: cardiovascular, ...
(Date:5/4/2015)... N.J. , May 4, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... multiple countries worldwide, will report Q1 2015 financial ... 11, 2015.  CytoSorbents, management will ... that will recount both operational and financial progress ...
Breaking Medicine Technology:Unchained Labs Lets the UNit Loose 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 4CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3
... Inhibitex, Inc. (Nasdaq: INHX ) today announced that ... its common stock, at a purchase price of $4.10 per ... proceeds to Inhibitex from the sale of the shares, after ... to be approximately $44 million.  Inhibitex has granted the underwriters ...
... Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTCBB: ... Company,s therapeutic and preventative HIV vaccines at the 2011 World ... in Washington DC on Thursday, April 14.  Dr. Robinson,s invited ... cover the topic of recombinant viruses as vaccines. The talk ...
Cached Medicine Technology:Inhibitex Prices $47 Million Public Offering 2Inhibitex Prices $47 Million Public Offering 3GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress 2GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress 3
(Date:5/4/2015)... 2015 CCL, a top-ranked, global provider ... program to other leadership development consultancies. “The CCL ... and successful practitioners, expanding our capacity to drive results ... John R. Ryan, CCL President and CEO. , As ... Partner Network , it will schedule a one-on-one conference ...
(Date:5/4/2015)... New West Medicare is excited to ... to manage outpatient advanced imaging services for its members. ... its members are provided the right test at the ... with New West Medicare’s physicians and hospitals, Care to ... advanced imaging and provide an objective basis for informed ...
(Date:5/4/2015)... Sylvia Hawthorn-Deppen shared her experiences living with ... others in similar situations that they were not alone, in ... Discovery of New Energy” (published by Balboa Press). This year ... renewed press campaign. , “I have spent nearly 60 years ... says. “As an adolescent I got into trouble with an ...
(Date:5/4/2015)... Fast on the heels of Autism Awareness ... Allison Folmar, JD, join over 150 speakers in the ... Sunday, May 24, the conference presents "I Know You're ... interested in Ryan Hinds' recovery story? The book ... autism was written by Marcia Hinds, Ryan’s mom. ...
(Date:5/4/2015)... Sara Soulati, CEO of Global Cardio ... Los Angeles associated with the field of Enhanced External ... Sara Soulati Health For Life Program (SSHFLP). , The ... modification and disease prevention program. A provisional patent ... Patents and Trademarks Office and is now under review ...
Breaking Medicine News(10 mins):Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... chemically-modified version of a mitochondrial toxin long used to ... found to selectively inhibit two "survival proteins in ... step toward developing a molecularly-targeted drug that could eliminate ... therapy found in many types of cancers. ,scientists ...
... just how important it is for mothers-to-be to relax, by ... their offspring will develop cerebral palsy . ,Cerebral ... disability. ,Though the study was conducted on a ... sante et de la recherche medicale, the French public biomedical ...
... together to plug the site of injury in the form ... aggregation can block blood vessels and cause heart attack ... many molecules to platelet integrin alpha-IIb beta 3, and blockade ... clots. ,However, chronic use of oral drugs that ...
... for neuroblastoma that lands a one-two punch works best when ... of the first one, according to results of studies at ... tumor that arises from cells in the peripheral nervous system. ... by using the drug bevacizumab to block VEGF, a protein ...
... tobacco industrys deceptive practices have been aggressively quashed through ... Ibrahim , co-author of an analysis in the August ... ,In the article, Ibrahim tracks the rise and ... for the past 40 years. She chronicles industry strategies ...
... the long-standing claim that organic farming methods cannot produce ... can yield up to three times as much food ... on the same land. ,Researchers from the ... were almost equal on organic and conventional farms. ...
Cached Medicine News:Health News:Cell Toxin Inhibits Survival Protein in Cancer Cells 2Health News:Tumor Blood Flow can Improve Chemotherapy 2Health News:Tumor Blood Flow can Improve Chemotherapy 3Health News:Tobacco Industry Promotes Antismoking Campaigns 2Health News:Tobacco Industry Promotes Antismoking Campaigns 3Health News:Organic Farming can Feed the World, U-M Study Shows 2Health News:Organic Farming can Feed the World, U-M Study Shows 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: